Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | thyroid hormone receptor, beta | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | photoreceptor-specific nuclear receptor | thyroid hormone receptor, beta | 461 aa | 414 aa | 24.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | multiple epidermal growth factor-like domains 6 | 0.0107 | 0 | 0.5 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.0107 | 0 | 0.5 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.0107 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0107 | 0 | 0.5 |
Onchocerca volvulus | Arrow homolog | 0.0107 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0152 | 0.6508 | 0.6508 |
Loa Loa (eye worm) | hypothetical protein | 0.0107 | 0 | 0.5 |
Schistosoma mansoni | thyroid hormone receptor | 0.0176 | 1 | 1 |
Brugia malayi | Fibulin-1 precursor | 0.0107 | 0 | 0.5 |
Brugia malayi | Calcium binding EGF domain containing protein | 0.0107 | 0 | 0.5 |
Loa Loa (eye worm) | low-density lipoprotein receptor repeat class B containing protein | 0.0107 | 0 | 0.5 |
Loa Loa (eye worm) | bone morphogenetic protein 1b | 0.0107 | 0 | 0.5 |
Echinococcus granulosus | Mitotic checkpoint protein PRCC C terminal | 0.0152 | 0.6508 | 1 |
Brugia malayi | Low-density lipoprotein receptor repeat class B containing protein | 0.0107 | 0 | 0.5 |
Echinococcus multilocularis | Mitotic checkpoint protein PRCC, C terminal | 0.0152 | 0.6508 | 0.6508 |
Loa Loa (eye worm) | hypothetical protein | 0.0107 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0107 | 0 | 0.5 |
Schistosoma mansoni | thyroid hormone receptor | 0.0176 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0107 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 0.0282 um | PUBCHEM_BIOASSAY: Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.4716 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 7.0795 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.929 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP). (Class of assay: confirmatory) [Related pubchem assays: 1482, 1471 ] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.